Metraipolis › archive › dc_0beeb8b8d95b

CDK9 and hematologic malignancies: pioneering novel therapeutic approaches — Europe PMC PMID:42201387

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42201387
DOI
10.1007/s10238-[numero omesso]-3
License (as archived)
solo-consultazione
Archived
2026-11-01T06:16:54.920Z
SHA-256 of the archived text
7d20bd76f643989f9a81b88729fd1946a20949d714930fa0f0cdd983fd1b4681
Stable URL of this page
https://metraipolis.com/documento/dc_0beeb8b8d95b

How to cite

CDK9 and hematologic malignancies: pioneering novel therapeutic approaches — Europe PMC PMID:42201387 — Europe PMC (en), https://europepmc.org/article/MED/42201387 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0beeb8b8d95b (Metraipolis archive dc_0beeb8b8d95b, sha256 7d20bd76f643989f9a81b88729fd1946a20949d714930fa0f0cdd983fd1b4681)
BibTeX
@misc{dc0beeb8b8d95b,
  title = {CDK9 and hematologic malignancies: pioneering novel therapeutic approaches — Europe PMC PMID:42201387},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42201387},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0beeb8b8d95b; sha256 7d20bd76f643989f9a81b88729fd1946a20949d714930fa0f0cdd983fd1b4681},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42201387. Agents can read the archived copy with the MCP tool read_document.